.navbar .collapse { display: block; } .mobile-nav { max-height: none !important; } @media screen and (min-width: 1200px) { .navbar #basic-navbar-nav .navbar-nav { position: static !important; } }

Dr Jain on the Role of JAK Inhibition in Polycythemia Vera and Myelofibrosis

EP. 1: Dr Jain on the Role of Ruxolitinib in Polycythemia Vera and Myelofibrosis

October 6th 2025

Akriti G. Jain, MD, discusses the role of ruxolitinib for the treatment with polycythemia vera and myelofibrosis.

EP. 2: Dr Jain on Treatment Decision-Making With JAK Inhibitors in Myelofibrosis

October 13th 2025

Akriti G. Jain, MD, details the treatment decision-making of JAK inhibitors for the treatment of patients with myelofibrosis.

EP. 3: Dr Jain on Considerations for Sequencing JAK Inhibitors in Myelofibrosis

October 20th 2025

Akriti G. Jain, MD, discusses factors that affect treatment sequencing with JAK inhibitors for the treatment of patients with myelofibrosis.

EP. 4: Dr Jain on Persisting Gaps in Defining Disease Modification in Polycythemia Vera and Myelofibrosis

October 27th 2025

Akriti G. Jain, MD, detailed the current unmet needs in polycythemia vera and myelofibrosis, including how to define disease modification.